Gunter Hoglinger

2 months ago | cell.com | Ilse Dewachter |Gunter Hoglinger |Daniel J. Drucker |Roland Martin |Anne Bernadette Chang |Sanjay Haresh Chotirmall | +2 more

Main textAD remains a major societal challenge, but more than a century of research is gradually leading to an exciting (r)evolution in AD and other tauopathy trials. Initially, amyloid-beta-targeting trials faced significant failures, but recent successes with lecanemab (Clarity AD) and donanemab (TRAILBLAZER-ALZ 2) demonstrated substantial amyloid clearance and significant clinical benefits.

Jun 18, 2024 | nature.com | Wiebke Möbius |Eckhard Mandelkow |Nicoleta Carmen Cosma |Josef Priller |Andrea Kuhn |Kathrin Brockmann | +16 more

AbstractMinimally invasive biomarkers are urgently needed to detect molecular pathology in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Here, we show that plasma extracellular vesicles (EVs) contain quantifiable amounts of TDP-43 and full-length tau, which allow the quantification of 3-repeat (3R) and 4-repeat (4R) tau isoforms.

Sep 29, 2023 | neurologylive.com | Gunter Hoglinger

WATCH TIME: 4 minutes "It [AMX0035] has a strong component that plays on mitochondrial dysfunction, which is the total residual component, and then the sodium phenylbutyrate component which plays and stabilizes the unfolded protein response." Earlier this year, Amylyx Pharmaceuticals announced a new trial, ORION, to assess the safety and efficacy of AMX0035 (Relyvrio), a previously approved therapy for amyotrophic lateral sclerosis (ALS), in patients with progressive supranuclear palsy (PSP),...

Sep 21, 2023 | neurologylive.com | Gunter Hoglinger

WATCH TIME: 4 minutes"The most important aspects when choosing patients for this trial is to have specificity for the underlying neurobiology. We know that possible and probably patients with Richardson syndrome, as diagnosed by the MDS criteria, have a high specificity of more than 90% to have an underlying tau pathology."Progressive supranuclear palsy (PSP) is a rare, progressive, and fatal tauopathy that affects body movements, walking and balance, and eye movement.